---
title: "Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287906180.md"
description: "Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News"
datetime: "2026-05-28T03:05:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287906180.md)
  - [en](https://longbridge.com/en/news/287906180.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287906180.md)
generator: "portal-rs"
---

# Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | ZBIO Stock News

### Related Stocks

- [ZBIO.US](https://longbridge.com/en/quote/ZBIO.US.md)

## Related News & Research

- [ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch](https://longbridge.com/en/news/280029591.md)
- [Zenas BioPharma 2025 10‑K: $10.0M revenue, GAAP loss $8.44/share](https://longbridge.com/en/news/279256807.md)
- [Spruce Biosciences targets Q4 2026 BLA filing for TA-ERT in Sanfilippo syndrome type B after FDA meetings](https://longbridge.com/en/news/296784399.md)
- [Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA | CAPR Stock News](https://longbridge.com/en/news/296796113.md)
- [Vanda says EU grants orphan drug status to imsidolimab for generalized pustular psoriasis](https://longbridge.com/en/news/296776870.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**